Biomarkers that reflect immune activation or dysfunction will be important in the management of infectious diseases

Biomarkers in Medicine

Volumn 5, Issue 2, 2011, Pages 109-112

  Gaudieri, Silvana ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA1 INTERFERON; INTERLEUKIN 29; PEGINTERFERON ALPHA; RIBAVIRIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; VIRUS VACCINE;

CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFECTION; LIFE EXPECTANCY; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PREVALENCE; REVIEW; SIDE EFFECT; TUBERCULOSIS; VIRUS LOAD;

BIOLOGICAL MARKERS; CHEMOKINES; COMMUNICABLE DISEASES; HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM; SEPSIS; TREATMENT OUTCOME;

EID: 79953860676     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.11.22     Document Type: Review

References (14)

1. Chakera A, Lucas A, Lucas M: Surrogate markers of infection: interrogation of the immune system. Biomarkers Med. 5(2), 131-148 (2011).
2. Faix JD: Established and novel biomarkers of sepsis. Biomarkers Med. 5(2), 117-130 (2011).
3. Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR: Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomarkers Med. 5(2), 171-186 (2011).
4. Oliver BG, Price P: The search for biomarkers of immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. Biomarkers Med. 5(2), 149-154 (2011).
5. Schmidt J, Thimme R, Neumann-Haefelin C: Host genetics in immune-mediated hepatitis C clearance. Biomarkers Med. 5(2), 155-169 (2011).
6. Suppiah V, Moldovan M, Ahlenstiel G et al.: IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy Nat. Genet. 41(10), 1100-1104 (2009).
7. Thomas DL, Thio CL, Martin MP et al.: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265), 798-801 (2009).
8. Rauch A, Kutalik Z, Descombes P et al.: Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138(4), 1338-1345 (2010).
9. Tanaka Y, Nishida Y, Sugiyama M et al.: Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009).
10. Ge D, Fellay J, Thompson AJ et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
11. Mallal S, Phillips E, Carosi G et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
12. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA: Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296(5572), 1439-1443 (2002). (Pubitemid 34553083)
13. Gaudieri S, Rauch A, Park LP et al.: Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J. Virol. 80(22), 11094-11104 (2006). (Pubitemid 44706550)
14. Keane N, John M: Biomarkers of natural and vaccine immunity against HIV. Biomarkers Med. 5(2), 113-116 (2011).